Citations

Mayo Clinic

Showing 10 of 108602 citations.

Prospective study of proton‐beam radiation therapy for limited‐stage small cell lung cancer
Rwigema, Jean‐Claude M. , Lin, Liyong , Levin, William P., Evans, Tracey L. , Rengan, Ramesh , Langer, Corey J. , Cohen, Roger B. , Simone, Charles B. , Verma, Vivek , Berman, Abigail T. , Aggarwal, Charu , Simone, Charles B , Lin, Liyong

Cancer | July 5, 2017 | Volume: 123 | Issue: 21 | Pages: 4244-4251

10.1002/cncr.30870 | PMID 28678434 Get It

BACKGROUNDExisting data supporting the use of proton‐beam therapy (PBT) for limited‐stage small cell lung cancer (LS‐SCLC) are limited to a single 6‐patient case series. This is the first prospective study to evaluate clinical outcomes and toxicities of PBT for LS‐SCLC.METHODSThis study prospectively analyzed patients with primary, nonrecurrent LS‐SCLC definitively treated with PBT and concurrent chemotherapy from 2011 to 2016. Clinical backup intensity‐modulated radiotherapy (IMRT) plans were generated for each patient and were compared with PBT plans. Outcome measures included local control (LC), recurrence‐free survival (RFS), and overall survival (OS) rates and toxicities.RESULTSThirty consecutive patients were enrolled and evaluated. The median dose was 63.9 cobalt gray equivalents (range, 45‐66.6 cobalt gray equivalents) in 33 to 37 fractions delivered daily (n = 18 [60.0%]) or twice daily (n = 12 [40.0%]). The concurrent chemotherapy was cisplatin/etoposide (n = 21 [70.0%]) or carboplatin/etoposide (n = 9 [30.0%]). In comparison with the backup IMRT plans, PBT allowed statistically significant reductions in the cord, heart, and lung mean doses and the volume receiving at least 5 Gy but not in the esophagus mean dose or the lung volume receiving at least 20 Gy. At a median follow‐up of 14 months, the 1‐/2‐year LC and RFS rates were 85%/69% and 63%/42%, respectively. The median OS was 28.2 months, and the 1‐/2‐year OS rates were 72%/58%. There was 1 case each (3.3%) of grade 3 or higher esophagitis, pneumonitis, anorexia, and pericardial effusion. Grade 2 pneumonitis and esophagitis were seen in 10.0% and 43.3% of patients, respectively.CONCLUSIONSIn the first prospective registry study and largest analysis to date of PBT for LS‐SCLC, PBT was found to be safe with a limited incidence of high‐grade toxicities. Cancer 2017;123:4244–4251. © 2017 American Cancer Society.
A Phase 2A Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Haemodynamic Effects of BMS-986231 in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction
Tita, Cristina , Gilbert, Edward M. , Bakel, Adrian B. Van , Grzybowski, Jacek , Haas, Garrie J. , Dunlap, Stephanie H., Klapholz, Marc, Patel, Parag C. , Pfister, Roman , Seidler, Tim , Shah, Keyur B. , Zieliński, Tomasz , Venuti, Robert, Cowart, Douglas, Foo, Shi Yin, Vishnevsky, A. A., Jarrah, Mohammad , Gottlieb, Stephen S. , Mitrović, Veselin L.

European Journal of Heart Failure | July 5, 2017 | Volume: 19 | Issue: 10 | Pages: 1321-1332

10.1002/ejhf.897 | PMID 28677877 Get It

Abstract Aims This study was designed to evaluate the safety, tolerability and haemodynamic effects of BMS-986231, a novel second-generation nitroxyl donor with potential inotropic, lusitropic and vasodilatory effects in patients hospitalized with decompensated heart failure and reduced ejection fraction (HFrEF). Methods and results Forty-six patients hospitalized with decompensated HFrEF were enrolled into four sequential dose-escalation cohorts in this double-blind, randomized, placebo-controlled Phase 2a study. Patients with baseline pulmonary capillary wedge pressure (PCWP) of ≥20 mmHg and a cardiac index of ≤2.5 L/min/m2 received one 6-h i.v. infusion of BMS-986231 (at 3, 5, 7 or 12 µg/kg/min) or placebo. BMS-986231 produced rapid and sustained reductions in PCWP, as well as consistent reductions in time-averaged pulmonary arterial systolic pressure, pulmonary arterial diastolic pressure and right atrial pressure. BMS-986231 increased non-invasively measured time-averaged stroke volume index, cardiac index and cardiac power index values, and decreased total peripheral vascular resistance. There was no evidence of increased heart rate, drug-related arrhythmia or symptomatic hypotension with BMS-986231. Analyses of adverse events throughout the 30-day follow-up did not identify any toxicities specific to BMS-986231, with the potential exception of infrequent mild-to-moderate headaches during infusion. There were no treatment-related serious adverse events. Conclusions BMS-986231 demonstrated a favourable safety and haemodynamic profile in patients hospitalized with advanced heart failure. Based on preclinical data and these study's findings, it is possible that the haemodynamic benefits may be mediated by inotropic and/or lusitropic as well as vasodilatory effects. The therapeutic potential of BMS-986231 should be further assessed in patients with heart failure.
A Severe Case of Congenital Thrombotic Thrombocytopenia Purpura Resulting From Compound Heterozygosity Involving a Novel ADAMTS13 Pathogenic Variant
Conboy, Erin , Partain, Paige , Kluge, Michelle L. , Arndt, Carola, Rodriguez, Vilmarie , Warad, Deepti , Chen, Dong , Partain, Paige

Journal of Pediatric Hematology/Oncology | July 4, 2017 | Volume: 40 | Issue: 1 | Pages: 60-62

10.1097/mph.0000000000000895 | PMID 28678087 Get It

We report a 9-year-old Chinese girl with congenital thrombotic thrombocytopenic purpura found to be a compound heterozygote for 2 pathogenic variants in the ADAMTS13 gene, including a novel variation. The girl suffered from recurrent, life-threatening episodes of thrombocytopenia and hemolysis, and laboratory testing showed ADAMST13 enzyme activity of <5%. Sequencing of the ADAMTS13 gene revealed a previously reported missense variant, c.1787C>T (p.Ala596Val), and a novel duplication defined as c.1007_1025dup19 (p.Asp343Leufs*53); the duplication is predicted to result in a premature stop codon and protein truncation. We propose that this novel variant is partly responsible for the patient’s early-onset and severe phenotype.
Outcomes and Complications of Reconstruction with Use of Free Vascularized Fibular Graft for Spinal and Pelvic Defects Following Resection of a Malignant Tumor
Rose, Peter S. , Bakri, Karim , Wagner, Eric R. , Yaszemski, Michael J. , Sim, Franklin H. , Moran, Steven L. , Houdek, Matthew T. , Wagner, Eric R

Journal of Bone and Joint Surgery | July 4, 2017 | Volume: 99 | Issue: 13 | Pages: e69

10.2106/jbjs.16.01458 | PMID 28678130 Get It

Background: Following resection of malignant tumors of the spine and pelvis, reconstructive surgeons often face large structural defects. Unlike reconstruction in the extremities, wherein a free vascularized fibular graft (FVFG) is a highly utilized option for segmental osseous reconstruction, there are limited data on the use of an FVFG in the spine and pelvis. The aim of this study was to review our institution’s experience with reconstruction with use of an FVFG following oncological resection in the spine and pelvis. Methods: We reviewed 24 cases involving the use of an FVFG in reconstruction of segmental osseous defects of the spine and pelvis following oncological resection from 2000 to 2015. The cohort consisted of 12 male and 12 female patients with a mean age of 37 years and a mean follow-up of 5 years. Fifty-four percent of the reconstructions were spinopelvic or sacropelvic. Results: The overall 2, 5, and 10-year rate of survival was 76%, 55%, and 37%, respectively. With regard to disease-free survival, the overall 2, 5, and 10-year rate was 81%, 72%, and 48%. The overall rate of union was 86%, with a mean time to union of 7 months. Complications were common, with 83% of the patients sustaining at least 1 postoperative complication. Following the procedure, the mean Musculoskeletal Tumor Society rating was 53%. Conclusions: An FVFG provides a durable means of reconstruction of osseous defects in the spine and pelvis. Although patient function was acceptable following these large reconstructions, the rate of postoperative complications was high. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
The Evolution of the Cup-Cage Technique for Major Acetabular Defects
Sculco, Peter K. , Hanssen, Arlen D. , Lewallen, David G. , Ledford, Cameron K. , Abdel, Matthew P.

Journal of Bone and Joint Surgery | July 4, 2017 | Volume: 99 | Issue: 13 | Pages: 1104-1110

10.2106/jbjs.16.00821 | PMID 28678123 Get It

Background: Complex acetabular reconstruction for major bone loss can require advanced methods such as the use of a cup-cage construct. The purpose of this study was to review outcomes after the initial development of the cup-cage technique and the subsequent evolution to the use of a half cup-cage construct. Methods: We performed a retrospective, single-center review of 57 patients treated with cup-cage reconstruction for major acetabular bone loss. All patients had major acetabular defects graded as Paprosky Type 2B through 3B, with 34 (60%) having an associated pelvic discontinuity. Thirty patients received a full cup-cage construct and 27, a half cup-cage construct. The mean follow-up was 5 years. Results: Both the full and half cup-cage cohorts demonstrated significantly improved Harris hip score (HHS) values, from 36 to 72 at a minimum of 2 years of follow-up (p < 0.05). Early construct migration occurred in 4 patients, with stabilization prior to 2-year follow-up in all but 1 patient. Incomplete, zone-3, nonprogressive acetabular radiolucencies were observed in 2 (7%) of the full cup-cage constructs and 6 (22%) of the half cup-cage constructs. One patient with a full cup-cage construct underwent re-revision of the acetabular component for progressive migration and aseptic loosening. Short-term survivorship free from re-revision for any cause or reoperation was 89% (83% and 96% for full and half cup-cage cohorts, respectively). Conclusions: Both full and half cup-cage constructs demonstrated successful clinical outcomes and survivorship in the treatment of major acetabular defects and pelvic discontinuity. Each method is utilized on the basis of individual intraoperative findings, including the extent and pattern of bone loss, the quality and location of host bone remaining after preparation, and the presence of pelvic discontinuity. Longer-term follow-up is required to understand the durability of these constructs in treating major acetabular defects and pelvic discontinuity. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
The incidence rates and survival of gallbladder cancer in the USA
Jaruvongvanich, Veeravich , Yang, Ju Dong , Peeraphatdit, Thoetchai , Roberts, Lewis R. , Yang, Ju Dong , Roberts, Lewis R

European Journal of Cancer Prevention | July 4, 2017 | Volume: 28 | Issue: 1 | Pages: 1-9

10.1097/cej.0000000000000402 | PMID 28683010 Get It

Gallbladder cancer is a rare malignancy in most countries. The racial and sociodemographic factors associated with its incidence and survival are poorly defined. We aimed to investigate population-based gallbladder cancer incidence and survival trends on the basis of clinical characteristics and sociodemographic factors in the USA. Gallbladder cancer incidence and survival data from 2001 to 2012 were obtained from 18 registries of the Surveillance, Epidemiology, and End Results database. Incidence rates and Joinpoint trends were calculated by demographic subgroup. Survival trends were assessed using Cox proportional hazard models. A total of 7769 patients were identified. The overall gallbladder cancer incidence rates did not significantly change during the 2001–2012 period. Incidence rates were three times higher in Hispanics and 1.6 times higher in Blacks compared with Whites. Over the time period, incidence rates significantly increased among Blacks and decreased among Hispanics. Male sex [hazard ratio (HR): 1.10, 95% confidence interval (CI): 1.03–1.17], older age (HR: 1.73, 95% CI: 1.53–1.96), and single and divorced statuses (HR: 1.19, 95% CI: 1.09–1.30 and 1.12, 95% CI: 1.01–1.24) were independently associated with shorter overall survival, whereas higher education (HR: 0.89, 95% CI: 0.82–0.97) and higher income (HR: 0.89, 95% CI: 0.82–0.96) were associated with longer survival. Furthermore, overall survival has improved in all races/ethnicities except for Hispanics and Blacks. The overall incidence rates for gallbladder cancer were stable during 2001–2012. Hispanics have the highest incidence rates, but the incidence rates in Blacks are on the rise.
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Muffly, Lori , Pasquini, Marcelo C. , Martens, Michael J. , Brazauskas, Ruta , Zhu, Xiaochun , Adekola, Kehinde , Aljurf, Mahmoud , Ballen, Karen K. , Baron, Frédéric , Beitinjaneh, Amer , Cahn, Jean‐Yves, Carabasi, Mathew, Chen, Yi‐Bin , Ciurea, Stefan O. , Copelan, Edward A. , D’Souza, Anita , Edwards, John , Foran, James M. , Freytes, César O. , Fung, Henry C., Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Ho, Vincent T. , Jakubowski, Ann A. , Luskin, Marlise R. , Martino, Rodrigo , Olin, Rebecca L. , Olsson, Richard F. , Pawarode, Attaphol , Peres, Edward, Rezvani, Andrew R. , Rizzieri, David A. , Schouten, Harry C. , Sabloff, Mitchell , Seftel, Matthew D. , Seo, Sachiko , Sorror, Mohamed L. , Wirk, Baldeep , Wood, William A. , Bajel, Ashish R. , Battiwalla, Minoo , Cahn, Jean‐Yves , Chhabra, Saurabh , Gale, Robert Peter , Giralt, Sergio , Lazarus, Hillard M. , Luskin, Marlise R , Maziarz, Richard Thomas , McCarthy, Philip L. , Nishihori, Taiga , Savani, Bipin N. , Szer, Jeff , Artz, Andrew , D'Souza, Anita , Olsson, Richard F , Martino, Rodrigo , Muffly, Lori , Sabloff, Mitchell , Martens, Michael J , Sorror, Mohamed , Wood, William A

Blood | July 3, 2017 | Volume: 130 | Issue: 9 | Pages: 1156-1164

10.1182/blood-2017-03-772368 | PMID 28674027 Get It

Key Points Over the last decade, allogeneic HCT has been increasingly administered in the United States to adults aged 70 and older with hematologic malignancies. Allogeneic transplant outcomes were reasonable; high comorbidity and ablative conditioning regimens were associated with inferior outcomes.
Protecting Adolescents' Right to Seek Treatment for Sexually Transmitted Diseases without Parental Consent: The Arizona Experience with Senate Bill 1309
Goodwin, Kimberly D., Winscott, Michelle, Scanlon, Megan, Hodge, James G. , Mickey, Tom, England, Bob, Taylor, Melanie M , Brown, Erin C. Fuse

Public Health Reports® | July 3, 2017 | Volume: 127 | Issue: 3 | Pages: 253-258

10.1177/003335491212700304 | PMID 22547855 Get It

In 2010, Senate Bill 1309 included language to repeal an existing Arizona law that enables minors younger than 18 years of age to seek diagnosis and treatment of sexually transmitted diseases (STDs) without parental consent. Numerous implications were identified that would have stemmed from parental consent provisions originally proffered in Senate Bill 1309. These implications included diminished access to essential health services among minors, exacerbated existing health disparities, increased health-care spending costs, and thwarted efforts to curb the spread of STDs. Lastly, minors would have been deprived of existing privacy protections concerning their STD-related medical information. This case study describes how collaborative advocacy efforts resulted in the successful amendment of Senate Bill 1309 to avert the negative sexual and reproductive health outcomes among adolescents stemming from the potential repeal of their existing legal right to seek STD treatment without parental consent.
Physicians Interrupting Patients
Phillips, Kari A. , Ospina, Naykky Singh , Phillips, Kari Ann, Singh Ospina, Naykky

JAMA | July 3, 2017 | Volume: 318 | Issue: 1 | Pages: 93

10.1001/jama.2017.6493 | PMID 28672309 Get It

Feasibility Assessment of Microwave Ablation for Treating Esophageal Varices
Šebek, Jan , Curto, Sergio , Eaton-Evans, Jimmy, Bouchier-Hayes, Jonathan, Ruvio, Giuseppe , Ganta, Chanran, Beard, Warren L., Buttar, Navtej , Song, Louis Wong Kee, Prakash, Punit

Journal of Medical Devices | July 3, 2017 | Volume: 11 | Issue: 3 | Pages: No page available

10.1115/1.4037187 Get It

Esophageal varices are a significant complication of portal hypertension. Endoscopic variceal ligation (EVL) is one of the clinical standards for treating these varices and preventing their hemorrhage. Limitations of EVL include the risk of stricture formation and postband ulcer bleeding due to the damage caused to the esophageal mucosa, as well as the need for multiple endoscopic treatment sessions to eradicate the varices. The goal of this study is to develop a device and evaluate the technical feasibility of microwave ablation to seal esophageal varices, while preventing thermal damage to the surface mucosal tissue. A microwave applicator with a directional radiation pattern was developed for endoscopic ablation of esophageal varices. Electromagnetic and bioheat transfer computational models were employed to optimize the design of the microwave applicator and evaluate energy delivery strategies for this application. Experiments in ex vivo and in vivo tissue were employed to verify simulation results. Simulations predicted enhanced heating performance of the antenna using an angled monopole radiating element. Further, simulations indicate that while the endoscopic cap attenuated electric fields in tissue, it also enhanced surface cooling of tissue, increasing the likelihood of preserving mucosal tissue. Experiments in ex vivo tissue indicated the feasibility of sealing veins with 77 W microwave power delivered for 30 s. In vivo experiments demonstrated the ability to seal veins, while preserving surface tissue. This study demonstrated the technical feasibility of microwave thermal ablation for treating esophageal varices using a 2.45 GHz water-cooled directional microwave applicator.